Ipsen set to rival Botox after duo of Phase III migraine wins - Pharmaceutical Technology

Ipsen claims that Dysport has become the first botulinum toxin therapy to demonstrate efficacy in episodic migraine. The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine. Ipsen’s claims that Dysport is the first botulinum toxin-based therapy to demonstrate efficacy in an episodic migraine trial. Credit: Orawan Pattarawimonchai / Shutterstock.com. Ipsen Pharmaceuticals’ Dysport (abobotulinumtoxinA), a Botox (onabotulinumtoxinA) competitor, could be on track for a label expansion after the drug posted a double Phase III win in two migraine indications. Within a duo of late-stage studies, which include the E-BEOND (NCT06047457) and C-BEOND…

Source: Pharmaceutical Technology